dorsaVi Unveils Artemis Labs Platform for Next-Generation Sensor Technologies

dorsaVi (ASX: DVL) has launched Artemis Labs, a wholly owned subsidiary focused on advancing robotics, artificial intelligence and sensor technologies.

The new division will merge dorsaVi’s FDA-cleared movement analytics with resistive random-access memory (RRAM) technology licensed from Nanyang Technological University in Singapore.

The company sees Artemis Labs acting as an innovation hub to extend human movement into robotics, digital health and intelligent systems.

Artemis Labs Strategy

Artemis Labs will consolidate all of dorsaVi’s research and development efforts under a dedicated platform, unifying expertise in AI, embedded systems and human–machine interfaces.

The unit will develop a proprietary database of human movement data to train AI models capable of running directly on low-power edge devices.

Applications are anticipated across multiple industries where responsive, real-time data is critical, such as robotics, healthcare, rehabilitation and industrial automation.

Key initiatives include camera-free motion tracking, adaptive wearable medical devices, zero-code robot training systems and gesture-based control interfaces.

By combining its movement capture technology with RRAM’s ultra-low power processing capability, Artemis aims to deliver neuromorphic systems that can both learn and act in dynamic environments.

Practical Technologies

Chair Gernot Abl said Artemis Labs was a natural evolution of dorsaVi’s mission to translate human biomechanics into practical technologies.

“The launch of Artemis Labs represents a bold step forward from measuring movement to empowering machines to understand, respond to, and replicate it,” Mr Abl said.

He added that Artemis strengthens the company’s clinical diagnostics business and positions it to enter new growth markets in robotics and digital health, while also expanding dorsaVi’s intellectual property portfolio, creating potential for licensing and partnerships with global technology companies.

The company said it expects Artemis to attract interest from both medical device and industrial automation sectors, where demand for intelligent sensing is increasing rapidly.

$5m Capital Raising

dorsaVi completed a $5 million placement earlier this week to fund its expansion into RRAM-enabled robotics and sensor technologies.

The raising, priced at $0.04 per share with free-attaching options, drew firm commitments from new and existing institutional investors.

The company will apply the proceeds to accelerate development of Artemis Labs, progress Reflex robotics platform trials, and strengthen sensor technology for healthcare applications.

Management said the proceeds provide a stronger balance sheet and flexibility to pursue international partnerships as Artemis Labs advances toward commercialisation.

Artemis expects settlement of the placement shares later this month, with initial project updates to follow.